BioMarin Pharmaceutical (BMRN) Earnings Analysis

BioMarin Pharmaceutical (BMRN) next reports earnings on 2026-08-03, consensus EPS 0.96 USD. Last quarter (2026-05-04) it missed with EPS 0.76 USD vs 0.78 USD est (-2.6%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E 41.71.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BMRN next report earnings?

Next earnings date2026-08-03
Consensus EPS estimate0.96 USD
Revenue estimate0.93B

BMRN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-040.76 USD0.78 USD-2.6%Miss
2026-02-23-0.24 USD0.1694 USD-241.7%Miss
2025-10-270.12 USD-0.15 USD+180%Beat
2025-08-041.44 USD0.861 USD+67.2%Beat
2025-05-011.13 USD0.94 USD+20.2%Beat
2025-02-190.92 USD0.54 USD+70.4%Beat
2024-08-050.96 USD0.3578 USD+168.3%Beat

Beat rate: 5/7 (71%) over reported quarters with consensus data.

BMRN valuation and analyst view

Trailing P/E41.71
Trailing EPS1.396 USD
Price / book1.81
Dividend yield0.00%
Market cap11.29B
Analyst consensusBuy (29 buy / 12 hold / 0 sell)
Avg price target84.5 USD

Related research pages

Frequently asked questions

When is BioMarin Pharmaceutical (BMRN)'s next earnings date?

BioMarin Pharmaceutical is next scheduled to report on 2026-08-03, with a consensus EPS estimate of 0.96 USD and revenue estimate of 0.93B.

Did BMRN beat earnings last quarter?

In its 2026-05-04 report, BMRN posted EPS of 0.76 USD versus a 0.78 USD estimate — a miss of 2.6%.

What is BMRN's earnings track record?

Over the last 7 reported quarters with consensus data, BMRN beat estimates 5 times (71%).

What is BMRN's current P/E ratio and EPS?

BMRN trades at a trailing P/E of 41.71 on trailing EPS of 1.396084094817062 USD.

What do analysts rate BMRN?

Analyst consensus is "Buy" across 41 ratings (0 strong buy, 29 buy, 12 hold, 0 sell, 0 strong sell). Average 12-month price target: 84.5 USD.